HPV & Cervical Cancer Screening: The New 2026 Self-Collection Guidelines

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. According to the Centers for Disease Control and Prevention (CDC), nearly all sexually active people will contract at least one type of HPV during their lifetime. There are over 200 types of HPV, but only about 14 are classified as high-risk strains that can lead to cancer.

Most HPV infections clear on their own within one to two years without causing any health problems. However, when a high-risk HPV infection persists, it can cause changes in cervical cells that may progress to precancer and, if left undetected and untreated, to cervical cancer. HPV types 16 and 18 are responsible for approximately 70 percent of all cervical cancer cases. HPV can also cause cancers of the vulva, vagina, anus, and oropharynx, though cervical cancer remains the most common HPV-related cancer in women.

Cervical cancer screening aims to detect precancerous changes in cervical cells before they develop into cancer. For decades, the Pap smear (also called a Pap test) was the sole screening method. The Pap test collects cells from the cervix, which are examined under a microscope for abnormalities.

In recent years, HPV testing has emerged as the preferred primary screening approach. Rather than looking for abnormal cells, HPV testing checks for the presence of high-risk HPV DNA or RNA in cervical or vaginal samples. Research consistently shows that primary HPV testing is more sensitive than the Pap smear alone for detecting precancerous lesions, meaning it catches more cases that need attention.

Current screening options include primary HPV testing alone (preferred), co-testing with both an HPV test and a Pap smear, or a Pap smear alone in settings where HPV testing is not available. According to current guidelines, screening should begin at age 25. Individuals aged 25 to 65 should be screened every five years with primary HPV testing, every five years with co-testing, or every three years with a Pap smear alone.

The most significant update in 2026 cervical cancer screening is the formal endorsement of self-collected vaginal samples for primary HPV testing. The ACS and HRSA guidelines now recognize that self-collection produces results comparable to clinician-collected cervical samples for detecting high-risk HPV.

This update was driven by several key factors. First, large-scale clinical trials involving tens of thousands of participants demonstrated that self-collected vaginal swabs have sensitivity and specificity for high-risk HPV detection that is non-inferior to clinician-collected samples. Second, the FDA has approved the first at-home HPV self-collection test kit, allowing individuals to collect a sample in the privacy of their own home and mail it to a certified laboratory. Third, approximately 30 percent of eligible individuals in the United States are not up to date on cervical cancer screening, with barriers including lack of access to a provider, discomfort with pelvic exams, time constraints, and cultural or personal preferences.

The guidelines emphasize that self-collection is not a replacement for comprehensive gynecologic care. It is an additional pathway to ensure that more people receive this critical cancer screening.

According to the 2026 guidelines, HPV self-collection is appropriate for individuals aged 25 to 65 who have a cervix and are due or overdue for cervical cancer screening. It is particularly beneficial for those who have not been screened in the past five or more years, those who face barriers accessing clinic-based screening such as living in rural areas or lacking transportation, individuals who experience anxiety or discomfort related to pelvic exams, and those with physical disabilities that make traditional pelvic exams challenging.

Self-collection is not recommended for individuals who are currently pregnant, those who have had a total hysterectomy with removal of the cervix for non-cancer reasons and have no history of high-grade precancer, individuals under age 25, or those who are currently being followed for an abnormal screening result. If you have a history of cervical precancer (CIN2 or higher) or are immunocompromised, discuss the best screening approach with your healthcare provider.

The self-collection process is straightforward. With FDA-approved at-home kits, you receive the test by mail with detailed instructions. You use a soft swab to collect a vaginal sample yourself, much like inserting a tampon. The swab is placed into a collection tube, sealed, and mailed to a CLIA-certified laboratory in the prepaid packaging provided.

For in-clinic self-collection, the process is similar. Your healthcare provider gives you a swab and instructions, and you collect the sample yourself in a private room. This option may be preferred by individuals who want guidance or immediate access to counseling about results.

Results are typically available within one to two weeks. The test detects the presence or absence of high-risk HPV strains. Some tests also provide genotyping information, specifically identifying whether HPV 16 or 18 is present, which helps guide the follow-up plan.

It is important to understand that self-collection tests for HPV only. They do not provide a Pap smear result. If your HPV test is positive, you will need an in-clinic visit for further evaluation.

A positive HPV result from a self-collected sample does not mean you have cervical cancer. It means that a high-risk HPV strain was detected and further evaluation is needed. The next steps depend on which HPV type is found.

If HPV 16 or 18 is detected, current guidelines recommend proceeding directly to colposcopy, a procedure in which a clinician uses a magnifying instrument to closely examine the cervix and take small tissue samples (biopsies) if any areas appear abnormal.

If a high-risk HPV type other than 16 or 18 is detected, the recommended next step is typically a clinician-performed Pap smear to check for abnormal cervical cells. If the Pap result is normal, you may be monitored with repeat testing in one year. If the Pap shows abnormalities, colposcopy is usually recommended.

If your HPV test is negative, you can return to routine screening in five years, provided you have no other risk factors. A negative HPV result is highly reassuring, as the negative predictive value of HPV testing exceeds 99 percent for high-grade cervical disease.

Each cervical cancer screening method has its own strengths. The traditional Pap smear directly examines cells for abnormalities and has been the standard for decades. However, it requires a speculum exam and clinician collection, and it is less sensitive than HPV testing for detecting precancerous lesions.

Clinician-collected HPV testing offers the highest sensitivity for detecting high-risk HPV and is the preferred primary screening method. It still requires a pelvic exam but provides a more objective, laboratory-based result.

Self-collected HPV testing offers comparable sensitivity to clinician-collected HPV testing for detecting high-risk HPV. Its primary advantages are convenience, privacy, and the elimination of the need for a speculum exam. Studies show that screening participation increases significantly when self-collection is offered, particularly among under-screened populations.

Co-testing, which combines a Pap smear and an HPV test, provides the benefit of both approaches but requires a clinical visit and speculum exam. It remains an acceptable option for individuals who prefer this approach.

Regardless of which method you use, the most important thing is to be screened. Any screening is better than no screening. If you are overdue, self-collection may be the option that helps you get started.